SCHEMBL3006873

SCHEMBL3006873

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4cc(C)c(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.52
MAPK1 P28482 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 8/20 0.52
HSD17B10 Q99714 3/20 0.52
USP2 O75604 2/20 0.52
RECQL P46063 1/20 0.52
ALDH1A1 P00352 7/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
L3MBTL1 Q9Y468 1/20 0.47
NPSR1 Q6W5P4 1/20 0.44
RAB9A P51151 1/20 0.43
HPGD P15428 2/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42
AR P10275 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3650093 0.93 MAPT (0.63) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3009984 0.91 LMNA (0.64) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3000497 0.90 LMNA (0.50) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3013258 0.90 SMN1; SMN2 (0.47) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3012405 0.89 SMN1; SMN2 (0.54) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3002151 0.89 MAPT (0.67) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3015002 0.88 LMNA (0.52) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3013300 0.88 MEN1 (0.52) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3005483 0.88 AR (0.56) LMNAMAPK1MEN1KMT2AMAPT
SCHEMBL3017906 0.88 MAPT (0.56) LMNAMAPK1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.